Abstract:Key Points The matrix metalloproteinases (MMPs) comprise a family of zinc-dependent endopeptidases that consist of more than 21 human MMPs and numerous homologues from other species. They can be divided into eight structural classes, three of which are membrane bound. The MMPs are synthesized as inactive zymogens and activated by proteinase cleavage. Their activity is regulated by endogenous inhibitors, including α2-macroglobulin; tissue inhibitors of metalloproteinases (TIMPs); small molecules with TIMP-like domains; and the membrane-bound inhibitor RECK (reversion-inducing cysteine-rich protein with kazal motifs). Direct evidence for a role of MMPs in tumour progression comes from xenograft experiments using cancer cells with decreased and increased expression levels of MMPs or TIMPs, and from carcinogenesis experiments with mice that either lack a specific Mmp or Timp-1 or have organ-specific Mmp or Timp-1 overexpression. MMPs are upregulated in almost every type of human cancer, and their expression is often associated with poor survival. Whereas some of the MMPs (for example, MMP-7) are expressed by the cancer cells, other MMPs (for example, MMP-2 and MMP-9) are synthesized by the tumour stromal cells, including fibroblasts, myofibroblasts, inflammatory cells and endothelial cells. MMPs can promote cancer progression by increasing cancer-cell growth, migration, invasion, metastasis and angiogenesis. MMPs exert these effects by cleaving a diverse group of substrates, which include not only structural components of the extracellular matrix, but also growth-factor-binding proteins, growth-factor precursors, receptor tyrosine kinases, cell-adhesion molecules and other proteinases. Several synthetic MMP inhibitors are undergoing Phase III clinical trials. Although a few encouraging results have been reported, some trials were prematurely terminated due to either lack of benefits or major adverse effects. The clinical trials have so far focused on patients with advanced-stage disease. Based on animal experiments, we would expect, however, that clinical efficacy might be improved either by using MMP inhibitors in the treatment of early disease (in combination with conventional therapy), or as preoperative and postoperative treatment to prevent surgical-induced micrometastatic spread and recurrence of the disease.

Research Progress of Promoting Function of Matrix Metalloproteinases in Gastric Cancer via Regulating Microenvironment

MMP Enzyme in Tumor Micro-environment: A Promising Target for Nano-medicine Delivery

Late Progresses in Research of ECM_1,MMP-9 and Gastric Cancer

Research progress of cytotoxin-associated gene A protein in the regulation of epithelial-mesenchymal transition in gastric cancer cells

Matrix Metalloproteinase Expression and Molecular Interaction Network Analysis in Gastric Cancer

Matrix Metalloproteinases in Tumorigenesis: an Evolving Paradigm

Expression of Matrix Metalloproteinase-7 Involving in Growth, Invasion, Metastasis and Angiogenesis of Gastric Cancer.

Progress on the Role and Mechanism of MT1-MMP in Tumor Metastasis

Recent Progress in the Study of Methylated Tumor Suppressor Genes in Gastric Cancer

The role of microRNAs in the gastric cancer tumor microenvironment

Progress in Study of Matrix Metalloproteinases and Tumour Invasion and Metastasis

[Progress of Study on the Roles of Matrix Metalloproteinases in the Pathogenesis of Hematologic Malignancies -- Review].

[Structure, Function and Regulation of MMPs].

The Role of Matrix Metalloproteinase in Epithelial-Mesenchymal Transition of Breast Cancer

Matrix Metalloproteinases: Regulators of the Tumor Microenvironment

Expressions and Clinical Significances of Wnt5a and MMP14 in Gastric Cancer

Endothelial-to-Mesenchymal Transition in the Tumor Microenvironment: Roles of Transforming Growth Factor-β and Matrix Metalloproteins

Progress in the clinical research of gastric cancer

Research progress of relationship between peritoneal microenvironment and peritoneal metastasis of gastric cancer

New functions for the matrix metalloproteinases in cancer progression

Advances in Clinical Research of Matrix Metalloproteinase Inhibitors as Anticancer Agents